PMID- 26782825
OWN - NLM
STAT- MEDLINE
DCOM- 20160714
LR  - 20181202
IS  - 1534-6242 (Electronic)
IS  - 1523-3804 (Linking)
VI  - 18
IP  - 2
DP  - 2016 Feb
TI  - Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists.
PG  - 7
LID - 10.1007/s11883-016-0558-5 [doi]
AB  - Cardiovascular disease is the leading cause of death among adults in the USA. 
      Both type 1 (T1DM) and type 2 diabetes mellitus (T2DM) are known risk factors for 
      cardiovascular disease. Despite the development of numerous effective 
      anti-glycemic therapies, we have been unable to completely mitigate 
      cardiovascular risk with glucose lowering alone, and prevention of cardiovascular 
      disease in patients with diabetes is primarily achieved with the use of 
      medications that address other risk factors such as anti-hypertensives or 
      statins. Glucagon-like peptide-1 (GLP-1) is a key hormone in the pathophysiology 
      of diabetes. GLP-1 agonists have been recently approved for the treatment of T2DM 
      as well as for chronic weight management. In this review, we aim to explore the 
      effects of GLP-1 agonists on cardiovascular health with a focus on 
      cardiometabolic variables and cardiac function.
FAU - Sarraju, Ashish
AU  - Sarraju A
AD  - Department of Medicine, Stanford University School of Medicine, Stanford, CA, 
      94305, USA.
FAU - Kim, Sun H
AU  - Kim SH
AD  - Division of Endocrinology, Stanford University School of Medicine, Stanford, CA, 
      94305, USA.
FAU - Knowles, Joshua W
AU  - Knowles JW
AD  - Division of Cardiovascular Medicine and Cardiovascular Institute, Stanford 
      University School of Medicine, Falk CVRC, Room CV273, MC 5406, 300 Pasteur Drive, 
      Stanford, CA, 94305, USA. knowlej@stanford.edu.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Atheroscler Rep
JT  - Current atherosclerosis reports
JID - 100897685
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - Cardiovascular Diseases/drug therapy/metabolism/*prevention & control/surgery
MH  - Endothelium/drug effects
MH  - Glucagon-Like Peptide 1/*agonists
MH  - Humans
MH  - Risk Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - ASCVD risk factors
OT  - Atherosclerosis
OT  - Cardiovascular disease
OT  - Diabetes
OT  - GLP-1 agonists
OT  - Glucagon-like peptide-1
OT  - Heart failure
OT  - Mortality
EDAT- 2016/01/20 06:00
MHDA- 2016/07/15 06:00
CRDT- 2016/01/20 06:00
PHST- 2016/01/20 06:00 [entrez]
PHST- 2016/01/20 06:00 [pubmed]
PHST- 2016/07/15 06:00 [medline]
AID - 10.1007/s11883-016-0558-5 [pii]
AID - 10.1007/s11883-016-0558-5 [doi]
PST - ppublish
SO  - Curr Atheroscler Rep. 2016 Feb;18(2):7. doi: 10.1007/s11883-016-0558-5.